Company Encyclopedia
View More
name
Curis
CRIS.US
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F.
1.946 T
CRIS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking161/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE312.10%A
    • Profit Margin-313.79%E
    • Gross Margin-91.88%E
  • Growth ScoreC
    • Revenue YoY13.56%B
    • Net Profit YoY19.63%B
    • Total Assets YoY-34.92%E
    • Net Assets YoY-68.19%E
  • Cash ScoreC
    • Cash Flow Margin-31.87%D
    • OCF YoY13.56%B
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreE
    • Gearing Ratio153.15%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

    Curis Inc. will present new clinical and preclinical data on emavusertib at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The data includes studies on primary and secondary CNS lymphomas, covering genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals. The results will be presented by researchers from leading institutions and have not yet been disclosed.

    Reuters·
    US
    CRIS
    +8.00%
    Reuters·
    US
    CRIS
    +8.00%

    Curis to Present at Upcoming 30th Annual SNO Meeting | CRIS Stock News

    Curis, Inc. (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib, an IRAK4 inhibitor, at the 30th Annual Society for Neuro-Oncology Meeting from November 19-23, 2025. Presentations will cover its efficacy in CNS Lymphoma and potential in improving immunotherapy for melanoma brain metastases. Emavusertib is under evaluation in multiple studies and has received Orphan Drug Designation for several conditions. Curis collaborates with Aurigene Discovery Technologies and has licensed rights to Erivedge® to Genentech.

    StockTitan·
    US
    CRIS
    +8.00%
    StockTitan·
    US
    CRIS
    +8.00%

    Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating

    Curis has received a Buy rating from analyst Soumit Roy of JonesTrading, with a price target of $5.00. This rating is based on Curis's upcoming clinical data updates and strategic focus on key trials, particularly in PCNSL and CLL. Promising results from a Phase 1 study of emavusertib in AML patients further support this positive outlook. Significant clinical data is expected at major medical conferences, enhancing Curis's prospects in the healthcare sector.

    Tip Ranks·
    US
    CRIS
    +8.00%
    Tip Ranks·
    US
    CRIS
    +8.00%

    Curis Inc. Earnings Call: Clinical Progress and Financial Gains

    Curis Inc. held its Q3 earnings call, highlighting positive clinical progress and improved financial performance. The company reported a reduced net loss of $7.7 million for Q3 2025, down from $10.1 million in Q3 2024, and reduced R&D expenses. Despite limited cash reserves of $9.1 million, Curis is optimistic about its TakeAim Lymphoma study and initial results from the AML triplet study. The company aims to secure additional capital and plans accelerated submissions for treatments in the U.S. and Europe over the next 12 to 18 months.

    Tip Ranks·
    US
    CRIS
    +8.00%
    Tip Ranks·
    US
    CRIS
    +8.00%

    Curis shares are trading lower. The company reported Q3 financial results.

    benzinga_article·
    US
    CRIS
    +8.00%
    benzinga_article·
    US
    CRIS
    +8.00%
    © 2025 Longbridge｜Disclaimer